參考資料

  1. XELJANZ Hong Kong Prescribing Information. Pfizer. September 2017. 
  2. Malemud, C. J. The role of the JAK/STAT signal pathway in. Ther Adv Musculoskelet Dis 10, 117–127 (2018).
  3. Strand V, Kremer J, Wallenstein G et al. Research & Therapy 17, 307 (2015).
  4. Fleischmann R, Kremer J, Cush J et al. N Engl J Med 367, 495-507 (2012).
  5. Aletaha D, Kivitz A, Valenzuela G, et al. Ann Rheum Dis. 2017;76(suppl 2):272-273. Abstract THU0186.
  6. Fleischmann, R. et al. The Lancet 390, 457–468 (2017).
  7. Cohen, S. et al. Presentation 963. Presented at ACR 2018, Chicago, USA. October 19-24, 2018.
  8. Wollenhaupt J, Lee EB, Curtis JR et al. Res Ther 21, 89 (2019).
  9. Xeljanz XR® (tofacitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version March 2019
  10. Lamba M, et al. J Clin Pharmacol 56, 1362-1371 (2016).
  11. Waterman, K. C. et al. J Control Release 134, 201–206 (2009).
  12. FAQS for XELJANZ® (tofacitinib citrate) | Safety Info. XELJANZ Available at: https://xeljanz.com/about-xeljanz/faq. (Accessed: 10th July 2019)
  13. Strand, V. et al. Arthritis Research & Therapy 17, 307 (2015).
  14. What Diet to Recommend to Patients with? NRAS. (Accessed June 2019 at, https://www.nras.org.uk/what-diet-to-recommend-to-patients-with)
  15. -friendly recipes. Foundation. Accessed 30 May 2019.
  16. Life with: What Will My Quality of Life Be Like? RASN. (Accessed on 2nd May 2019)
  17. Ezerioha, M. Life with : What Will My Quality of Life Be Like? (Accessed: 10th July 2019)
  18. Cooney, J. K. et al. J Aging Res 2011, (2011).
  19. Zhang, Z. et al. Immunotherapy 11, 321–333 (2019).

PP-XEL-HKG-0081 Aug 2019

Shut down